A survey of the clinical pipeline in neuroscience

[Display omitted] Many new first-in-class drugs for neuroscience indications have been introduced in the past decade including new treatments for migraine, amyotrophic lateral sclerosis, depression, and multiple sclerosis. However, significant unmet patient needs remain in areas such as chronic pain...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry letters Vol. 56; p. 128482
Main Authors Brown, Dean G., Wobst, Heike J.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 15.01.2022
Subjects
Alzheimer’s disease
Amyotrophic lateral sclerosis
Chronic pain
Chronic Pain - drug therapy
Depression
Epilepsy
Epilepsy - drug therapy
Humans
Mental Disorders - drug therapy
Neurodegeneration
Neurodegenerative Diseases - drug therapy
Neuroprotective Agents - chemistry
Neuroprotective Agents - therapeutic use
Neurosciences
DLK
TNFα
DPN
PPD
Epilepsy
HTS
JNK
ALS
MDD
GABAA
mAB
DEEs
SHE
Neurodegeneration
PHN
AD
Alzheimer’s disease
Amyotrophic lateral sclerosis
Depression
MAPK
Chronic pain
LOX
PD
DRG
PAM
Online AccessGet full text

Cover

More Information
Summary:[Display omitted] Many new first-in-class drugs for neuroscience indications have been introduced in the past decade including new treatments for migraine, amyotrophic lateral sclerosis, depression, and multiple sclerosis. However, significant unmet patient needs remain in areas such as chronic pain, neurodegeneration, psychiatric diseases, and epilepsy. This review summarizes some of the advanced clinical compounds for these indications. Additionally, current opportunities and challenges that remain with respect to genetic validation, biomarkers, and translational models are discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2021.128482